Citalopram Hydrobromide/Pipamperone Hydrochloride

氢溴酸西酞普兰/盐酸匹泮哌隆

Report date: 2023/04/21 13:58:48

Base Information

Drug NameCitalopram Hydrobromide/Pipamperone Hydrochloride
Drug Alias Name盐酸匹泮哌隆/氢溴酸西酞普兰Citalopram hydrobromide/Pipamperone匹泮哌隆+西酞普兰pipamperone + citalopramPipamperone Hydrochloride/Citalopram Hydrobromide +[6] 
ClassificationSmall molecules
Mechanisms of ActionSerotonin 2a (5-HT2a) receptor antagonistsDopamine D2 receptor antagonistsDopamine D4 receptor antagonists +[4] 
TargetsSerotonin 2a (5-HT2a) receptorDopamine D2 receptorDopamine D4 receptor +[4] 
Therapy Area/IndicationsDepressive Disorder, MajorDepression
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesUnited Kingdom
CombinationsYes Citalopram HydrobromidePipamperone Hydrochloride
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPharmaneuroboost Nv
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPharmaneuroboost Nv
Active IndicationsN/A
Inactive IndicationsDepressive Disorder, MajorDepression

Other Information

ATC CodeN/A
Related LinksN/A